Spero Therapeutics (SPRO) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in tebipenem HBr program for cUTI, including NDA resubmission and completion of global Phase 3 trial.

• Licensing partner GSK announced FDA PDUFA date for tebipenem HBr as June 18, 2026.

• Focused on fulfilling obligations under GSK license and exploring portfolio expansion opportunities.

Financial highlights

• Net income for Q4 2025 was $31.5 million, compared to a net loss of $(20.9) million in Q4 2024.

• Net income for full year 2025 was $8.6 million, versus a net loss of $(68.6) million in 2024.

• Total revenue for Q4 2025 was $41.3 million, up from $15.0 million in Q4 2024, driven by increased collaboration revenue from GSK and Pfizer.

• Full year 2025 revenue was $66.8 million, up from $48.0 million in 2024.

• Cash and cash equivalents as of December 31, 2025, were $40.3 million.

Outlook and guidance

• Cash and cash equivalents expected to fund operations into 2028.

• Awaiting FDA decision on tebipenem HBr NDA by June 18, 2026.

• Exploring opportunities to expand clinical-stage product portfolio.